Back pain has no shortage of sufferers and remarkably few treatments that actually address its root cause. Surgery remains the only real long-term option for intervertebral disc degeneration, a progressive breakdown of the spine's natural shock absorbers that affects a huge share of adults at some point in their lives. A study published in the journal Communications Biology and reported publicly starting August 6, 2026, from researchers at the Universities of Edinburgh and Bristol, offers the first real hint of an alternative, and it comes from an unexpected source: a drug already sitting on pharmacy shelves for an entirely different condition.

Starting from a gene already linked to human disc problems

The research, led by Dr. Erika Kague of the University of Edinburgh's Institute of Genetics and Cancer, focused on a gene associated with collagen IX, a protein that plays a structural role helping bind together the fibers within intervertebral discs. Previous human genetic research had repeatedly connected faults in this specific gene to early-onset disc problems, but the precise biological chain of events linking a faulty collagen IX gene to actual disc breakdown had remained poorly understood.

To investigate that chain of events directly, Kague's team turned to zebrafish, small freshwater fish increasingly used in biomedical research because their skeletal systems, despite obvious differences from humans, share enough underlying genetic and structural similarities to make them useful models for studying degenerative conditions. Researchers bred zebrafish lacking a working copy of the col9a1b gene, the fish equivalent of the human collagen IX gene already implicated in disc disease, and then tracked what happened to those fish's spines as they aged.

Watching disc disease unfold, one biological step at a time

What the research team observed as these genetically altered zebrafish aged closely mirrored the progression of human disc disease. Early on, the structural scaffolding within the fish's spinal ligaments began breaking down before any other visible changes appeared. That early scaffold breakdown was followed by mineral deposits accumulating within the affected tissue, a process that progressively hardened what should have remained flexible, cushioning material. Eventually, the accumulated mineralization led to spinal fusion, vertebrae effectively locking together in a way that closely resembles the kind of vertebral fusion seen in advanced human intervertebral disc degeneration.

That step-by-step progression, structural breakdown, then mineral buildup, then fusion, gave researchers something genuinely valuable: a clear, observable sequence of biological events they could potentially interrupt at multiple different points, rather than a single, poorly understood endpoint with no visible pathway leading up to it.

An existing osteoporosis drug interrupted the damage

Having mapped that progression, the research team tested whether existing drugs could interrupt it. The most striking result came from testing a bisphosphonate, a class of bone-protecting medication already widely prescribed to treat osteoporosis by slowing the breakdown of bone tissue. When administered to the genetically altered zebrafish, the bisphosphonate blocked the mineral buildup driving the fish's spinal fusion, directly interrupting the disease process at one of its key intermediate stages.

That finding matters considerably given the drug's existing regulatory and safety profile. Bisphosphonates have already been used clinically in humans for decades to treat osteoporosis, meaning any potential repurposing toward disc degeneration wouldn't require developing an entirely new compound from scratch, but rather testing an existing, well-characterized medication against a new therapeutic target.

Diet and fat metabolism turned out to matter too

The bisphosphonate wasn't the only intervention that worked. Researchers also found that simply restricting the fish's food intake reduced spinal fusion, as did administering separate drugs specifically designed to dampen fat metabolism. That second finding points toward a genuinely distinct biological pathway from the phosphate-related mineral buildup that the bisphosphonate addressed, suggesting fat metabolism plays its own independent role in driving disc degeneration alongside the mineral deposition process.

Together, these results point researchers toward two separate but complementary therapeutic targets worth pursuing further: phosphate handling within spinal tissue, and broader lipid or fat metabolism regulation. Having two independent biological levers to potentially intervene on, rather than just one, meaningfully broadens the range of drug development strategies researchers might pursue going forward.

Why the researchers describe this as a genuine turning point

Dr. Kague was direct about how significant this shift feels after years of limited treatment options. "For decades, surgery has been the only real answer for disc disease," she said, framing the study's identification of specific, targetable biological pathways as opening up genuinely new therapeutic possibilities rather than simply adding incremental detail to an already well-understood condition.

Dr. Jef Grainger, Executive Director of Bioscience Advancing Knowledge at the UK's Biotechnology and Biological Sciences Research Council, which helped fund the work, situated the findings within a broader case for publicly funded basic science. "This research shows how publicly funded discovery bioscience can generate the knowledge needed to address major health challenges," Grainger said. "By revealing new knowledge of how healthy biological processes break down in ageing-related spinal disc degeneration, the study opens up promising avenues for future treatment development."

What still needs to happen before this reaches patients

It's worth being clear about exactly what this study does and doesn't establish. The findings come from a genetically engineered zebrafish model, not from human clinical trials, and while zebrafish have proven useful for studying various skeletal and degenerative conditions, translating a finding from fish to confirmed clinical benefit in human patients typically requires substantially more research, including testing in additional animal models better suited to mammalian spinal anatomy, followed eventually by human clinical trials specifically designed to test bisphosphonates or fat-metabolism-targeting drugs against disc degeneration rather than their currently approved uses.

That said, because bisphosphonates already carry an established human safety profile from decades of osteoporosis treatment, the practical pathway toward testing this specific drug class against disc degeneration in human patients is considerably shorter than it would be for an entirely novel compound requiring safety testing from scratch.

A widespread problem finally gaining a mechanistic foothold

Intervertebral disc degeneration affects an enormous share of the adult population at some point in their lives and represents a substantial, ongoing burden on both patients and healthcare systems, given that no medications currently exist capable of halting or reversing the condition's progression once it begins. A study capable of mapping out the specific biological sequence driving that degeneration, and then demonstrating that an already-approved medication can interrupt part of that sequence, represents a genuinely meaningful step for a condition that has offered clinicians remarkably few tools beyond eventual surgical intervention. Whether bisphosphonates or fat-metabolism-targeting drugs eventually prove effective against human disc degeneration remains to be tested directly, but this study gives researchers a considerably clearer roadmap for pursuing that question than existed before.

---

*Sources cited in this article include the peer-reviewed study "Targeted modulation of phosphate and lipid metabolism reduces ligament mineralization in col9a1b deficient zebrafish," published in Communications Biology, and reporting from ScienceDaily, MedicalXpress, News-Medical.net, EurekAlert, and Mirage News covering research led by Dr. Erika Kague at the University of Edinburgh. All figures reflect reporting available as of August 6, 2026.*